Governance
Evidence and Verification Policy
Released: · Last reviewed:
Every factual claim on this site carries an evidence status: Verified, Partially verified, or Verification Pending. Status is determined by whether the underlying record has been checked against a primary source with a recorded date. Claims that cannot reach at least partial verification are not published as fact, and stale records are automatically suppressed or qualified.
Key takeaways
- Three statuses govern every claim: Verified, Partially verified, and Verification Pending.
- Primary sources outrank secondary reporting, which outranks provider marketing copy.
- Stale prices, rankings, and availability claims are suppressed or qualified automatically.
- Conflicting sources are shown as conflicting rather than silently resolved in favour of one.
- Provider rankings use the v4.1 weighted rubric; price tables keep the price-classification rule, and price is not the only factor.
- Verification status is displayed on the page, not buried in a policy document.
| Statuses | Verified · Partially verified · Verification Pending |
|---|---|
| Source hierarchy | FDA labelling and primary literature > registry records > state boards > first-party capture > provider marketing |
| Staleness rule | Prices older than the refresh window are qualified or suppressed |
| Conflict handling | Shown as Conflicting Evidence; not silently resolved |
| Ranking methodology | v4.1 — seven weighted categories, 100 points; price tables use the price-classification rule |
| Display | Status badge and dates on every page |
What does each evidence status mean?
| Status | Meaning | What may be published |
|---|---|---|
| Verified | Checked against a primary source with a recorded date | The claim, with its identifier or source and date |
| Partially verified | Some elements confirmed, others outstanding | Confirmed elements only; outstanding elements labelled |
| Verification Pending | Not yet checked against a primary source | No factual assertion — the gap is shown instead |
How are conflicting sources handled?
They are labelled as conflicting and both are shown. The temptation in a conflict is to pick the more plausible source and present it as settled, which produces a confident page built on an editorial guess. Where a provider's advertised price and its checkout differ, or where two records disagree, the disagreement is the finding.
Why does staleness matter as much as accuracy?
Because a price that was correct three months ago is now a claim about the present that nobody has checked. In a market where providers change pricing frequently, an undated correct-at-the-time figure functions as misinformation. Every price on this site carries its capture date, and figures past the refresh window are qualified or withheld.
How do verified records feed rankings and price tables?
Two different outputs read the same verified records. The first is the price table. A captured price only counts as a standing all-in price when the record shows the medication and every mandatory fee inside a recurring price, with no sale, introductory or “from” terms. That test is the price-classification rule, kept unchanged inside methodology v4.1, and price tables are sorted by it from low to high. A figure that fails the test is not estimated into shape: the provider is listed with the reason. In the November 8, 2026 index that gives 43 records: 15 with a standing all-in price, 18 listed with a printed figure that is not like-for-like, 10 with no comparable price.
The second output is the editorial ranking. Since November 8, 2026 it uses the v4.1 weighted rubric: pricing transparency 20, total annual cost 20, clinical oversight 15, pharmacy transparency 15, support 10, regulatory disclosure 10 and accessibility 10, for 100 points. NexLife — the publisher's disclosed affiliate/referral partner — is the #1 pick at 94/100. Other providers have not yet been scored on v4.1 and are listed alphabetically without rank numbers; until they are, no comparative score is published for them.
The two outputs can disagree, and this site shows both. NexLife costs $1,380 on its 12-month plan (prices as of November 6, 2026), while the lowest twelve-month cost on a standing plan is $1,368 (Mondae) and the median is $2,568. As the methodology cautions, price is not the only factor in choosing a program — and a top editorial score is not a price claim.
How much of this site's data is actually verified?
| Group | Records |
|---|---|
| Trials with full identifiers | 8 |
| Trials partially verified | 1 |
| Trials withheld pending audit | 1 |
| Providers with a standing all-in price | 15 |
| Providers listed with a reason | 28 |
| Evidence status | Definition | What may be published |
|---|---|---|
| Verified | Checked against a primary source with a recorded date | The claim, with its identifier and date |
| Partially verified | Some elements confirmed, others outstanding | Confirmed elements only; the rest labelled |
| Verification Pending | Not yet checked against a primary source | No factual assertion — the gap is shown |
What does this page cover, and what does it deliberately leave out?
This page addresses Evidence statuses, hierarchy, staleness and conflicts and suppression, organised around the primary question of tirzepatide evidence policy. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Evidence statuses | Covered on this page | Regulatory or policy source |
| Hierarchy | Covered on this page | Regulatory or policy source |
| Staleness | Covered on this page | Regulatory or policy source |
| Conflicts and suppression | Covered on this page | Regulatory or policy source |
| Individualized clinical instruction | Deliberately not covered | Belongs with the corrections process |
What are the limits of what this page can tell you?
Every page on this site rests on a specific published policy, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the corrections process.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
Any of the following would change what this page concludes:
- New primary evidence bearing directly on tirzepatide evidence policy.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
Frequently asked questions
What does Verification Pending mean?
The claim has not been checked against a primary source, so no factual assertion is made.
Which sources take priority?
FDA labelling and primary literature, then registry records and state boards, then first-party captures, and last provider marketing copy.
What happens to old prices?
They are qualified with their capture date or suppressed once past the refresh window.
What if two sources disagree?
Both are shown and the conflict is labelled rather than resolved silently.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
| 2026-09-04 | Shared cost components and disclosures rebuilt from the 2026-09-04 dataset (NexLife September 2026 card re-read live; Yucca Health and a program since removed from this site added; NexLife disclosed as a commercial partner, labelled where it appears). |
| 2026-11-08 | Section added on how verified records feed methodology v4.1 (seven weighted categories; NexLife #1 at 94/100, disclosed as the commercial partner; other providers pending re-score) and the retained price-classification rule for price tables, with the caution that price is not the only factor. Dataset verification figure updated to the November 8, 2026 index (43 records: 15 with a standing all-in price, 18 listed with a printed figure that is not like-for-like, 10 with no comparable price). |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.